Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit ...
San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...
Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...
Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. | After repeatedly wowing investors, Roche’s star eye med ...
The Sewanhaka Central High School District recognized multiple student achievements at its Jan. 28 Board of Education meeting.
Hosted on MSN13h
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform WellSwiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...
Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback